BCLI Brainstorm Cell Therapeutics, Inc.: רווח למניה ב-12 החודשים האחרונים

The specifics of manual cell modification on the Nuown platform limit production scales, which is offset by the high cost of the drugs. The annual percentage change in earnings per share (TTM) visualizes this financial dynamic, where 37.70 shows the level of this metric. Brainstorm Cell (BCLI) is diversifying risks by developing treatments for sclerosis and ALS, seeking accelerated FDA approval for its developments.

The scale of the Brainstorm Cell (BCLI) biotech business is reflected in the annual growth trend of net income per share TTM. This indicator captures the rolling annual expansion rate of profit, adjusted for one-off factors. The calculation measures the efficiency of intellectual property monetization amid tight Fed policy. For a company with the closed patent perimeter of NurOwn, this metric confirms the commercial viability of therapy protocols. Steady growth in this indicator signals a transition from the R&D stage to capitalization.